ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Gilead Shares HIV Drug Technology

by Lisa M. Jarvis
August 13, 2012 | APPEARED IN VOLUME 90, ISSUE 33

Gilead Sciences will allow several generic drug firms to make and sell its HIV medicine emtricitabine, marketed as Emtriva, as well as fixed-dose combinations of emtricitabine with other HIV medicines, in developing countries. Gilead will transfer the manufacturing technology for emtricitabine to Mylan Laboratories, Ranbaxy Laboratories, and Strides Arcolab and provide funding to help the generic drug firms improve the manufacturing process, thereby lowering the cost of the medication. The goal is for Gilead’s Indian partners to produce high-enough volumes of the fixed-dose combinations of regimens containing emtricitabine to achieve price parity with widely used HIV regimens containing lamivudine.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment